Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.creatorAraújo, N
dc.creatorCosta, A
dc.creatorLopes, C
dc.creatorLopes-Conceição, L
dc.creatorFerreira, A
dc.creatorCarneiro, F
dc.creatorOliveira, J
dc.creatorMorais, S
dc.creatorPacheco-Figueiredo, L
dc.creatorRuano, L
dc.creatorCruz, VT
dc.creatorPereira, S
dc.creatorLunet, N
dc.description.abstractCognitive impairment is common among patients with different types of cancer, even before cancer treatment, but no data were reported among patients with prostate cancer (PCa), who may be at high risk due to advanced age. This study aims to estimate the prevalence of cognitive impairment before PCa treatment. Between February 2018 and April 2021, the NEON-PC cohort recruited 605 patients with PCa proposed for treatment at the Portuguese Institute of Oncology of Porto. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive performance. Participants with a MoCA < 1.5 standard deviations (SD) of age-and education-specific normative values were considered to have probable cognitive impairment (PCI) and were referred for a comprehensive neuropsychological assessment. Data from the population-based cohort EPIPorto (n = 351 men aged ≥40 years, evaluated in 2013–2015) were used for comparison. The prevalence of PCI was 17.4% in EPIPorto and 14.7% in NEON-PC (age-and education-adjusted odds ratio: 0.82, 95%CI: 0.58,1.18). Neuropsychological assessment was performed in 63 patients with PCa: 54.0% had cognitive impairment. These results suggest that the impact of PCa on cognitive performance could be negligible in the short term, contrary to what other studies have reported regarding other types of cancer. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
dc.description.sponsorshipThis study was funded by the European Regional Development Fund through the Operational Program Competitiveness and Internationalization, national funding from the Foundation for Science and Technology-FCT (Portuguese Ministry of Science, Technology and Higher Education) under the project ‘NEON-PC-Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017), and the Unidade de Investigação em Epidemiologia-Instituto de Saúde Pública da Universidade do Porto (EPIUnit; UIDB/04750/2020) and ITR (LA/P/0064/2020), financed by national funds from FCT. A.C., C.L., and S.M. were funded under the scope of the project ‘NEON-PC—Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017). S.M. also received funding under EPIunit-Junior Research-Prog Financing (UIDP/04750/2020). An individual PhD grant attributed to N.A. (SFRH/BD/119390/2016) was funded by FCT and the ‘Programa Operacional Capital Humano’ (POCH/FSE).
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04750/2020/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP/04750/2020/PT
dc.relation.ispartofCancers (Basel). 2022 Mar 7;14(5):1355. doi: 10.3390/cancers14051355.
dc.subjectCognitive dysfunction/epidemiology; Neuropsychological test; Prevalence study; Prostate cancer
dc.titlePrevalence of Cognitive Impairment before Prostate Cancer Treatment
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Saúde Pública da Universidade do Porto
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
araujo-c-2022.pdf475.47 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons